# Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"

> **NCT07021677** · PHASE2 · RECRUITING · sponsor: **Tata Memorial Centre** · enrollment: 18 (estimated)

## Conditions studied

- T Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Daratumumab Injection

## Key facts

- **NCT ID:** NCT07021677
- **Lead sponsor:** Tata Memorial Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-28
- **Primary completion:** 2026-08-28
- **Final completion:** 2026-08-28
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07021677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07021677, "Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07021677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*